LMR Partners’s SAB Biotherapeutics Warrant SABSW Stock Holding History

LMR Partners’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-539,588	Closed	-$19.4K	–	1548
2024 Q3	$19.4K	Buy	+539,588	New	+$20.2K	﹤0.01%	1123

Other funds holding SABSW

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

LMR Partners's SABSW Position: Q1 2026 in Review

LMR Partners opened a new position in SAB Biotherapeutics Warrant (SABSW) in Q1 2026: 539,588 shares worth $14.1K. The stake represents ﹤0.01% of the portfolio and ranks #1358 among its holdings. This is a return to the name: LMR Partners previously reported a position in SABSW as recently as Q3 2025.

LMR Partners first reported a position in SABSW in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.27M in Q1 2022. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

LMR Partners held 539,588 shares of SAB Biotherapeutics Warrant worth $14.1K as of Q1 2026.
SAB Biotherapeutics Warrant was a new LMR Partners position in Q1 2026.
SAB Biotherapeutics Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1358 holding.
LMR Partners first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and has held it in 16 quarters since.
LMR Partners's SAB Biotherapeutics Warrant position peaked at $1.27M in Q1 2022.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.